London Office | firstname.lastname@example.org | +44 (0) 207 451 4564
Kelly Curtin, a Managing Director on Torreya’s European team, advises clients on strategic transactions across the life sciences industry. She has 20 years of experience in investment banking, primarily in the healthcare industry.
Her experience includes strategic transactions across a wide spectrum of the life sciences, including biotechnology, pharma, specialty pharma, generics, healthcare services and medical devices. Kelly has led cross-border M&A, carve-outs, licensing transactions and divestments as well as executed a range of equity and debt financings.
Recent transactions on which Kelly has worked at Torreya include the acquisition of Dara Biosciences by Midatech plc, the licensing of European rights for Shield’s Feraccru to Norgine and the sale of MTPUS to Kanwa Holdings, an affiliate of Barings.
Before joining Torreya in 2014, Kelly was a Director in Credit Suisse’s Mergers & Acquisitions group in Chicago and London.
Kelly holds a B.A. in Law, Jurisprudence and Social Thought from Amherst College.
|License of |
Up to $306 million
|Sale of Midatech Pharma US Inc. to Kanwa Holdings LP, an affiliate of Barings LLC|
Up to $19 million
|Licensing of ex European rights for LYS-SAF302 to|
Up to $125 Millionwith committed payments of $29m plus royalties
|Licensing agreement for Feraccru® in Europe, Australia and New Zealand with|
£11 million upfront(plus up to £54.5m in milestones and 25-40% royalties)
Up to $30 million